Cargando…

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with few biomarkers to guide treatment options. Carbohydrate antigen 19.9 (CA19.9), the most frequently used biomarker for PDAC, is not sensitive and specific enough for the detection of the disease. This study aimed to evaluate ser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Dong, Jia, Li, Zhang, Lufang, Ma, Na, Zhang, Aimin, Zhou, Yunli, Ren, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125476/ https://www.ncbi.nlm.nih.gov/pubmed/29945294 http://dx.doi.org/10.1111/cas.13712

Ejemplares similares

Comparative study of CA242 and CA19-9 in chronic pancreatitis.
por: Furuya, N., et al.
Publicado: (1996)

Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
por: Kawa, S., et al.
Publicado: (1994)

Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer
por: Luo, Hai, et al.
Publicado: (2020)

The prognostic and predictive value of serum CA19.9 in pancreatic cancer
por: Humphris, J. L., et al.
Publicado: (2012)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction
por: Jia, Li, et al.
Publicado: (2022)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Intralobar pulmonary sequestration with aspergillus infection and elevated serum CA19-9 and CA242: a case report
por: Ge, Li, et al.
Publicado: (2021)

Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
por: Pasanen, P. A., et al.
Publicado: (1992)

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
por: Haglund, C., et al.
Publicado: (1989)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
por: Nilsson, O., et al.
Publicado: (1992)

Effects of natural orifice transluminal endoscopic radical resection of the colon and targeted therapy on immune response and blood CA199 and CA242 levels in colorectal cancer
por: Liu, Guiwei, et al.
Publicado: (2023)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program
por: Levink, Iris J. M., et al.
Publicado: (2023)

Performance evaluation of CA242 by flow fluorescence assay
por: Hou, Yanyan, et al.
Publicado: (2021)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer
por: Gu, Yuanlong, et al.
Publicado: (2023)

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9
por: Makawita, Shalini, et al.
Publicado: (2013)

Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer
por: Jahan, Rahat, et al.
Publicado: (2019)

Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives
por: Coppola, Alessandro, et al.
Publicado: (2022)

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991)

Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance
por: Jia, Fuxin, et al.
Publicado: (2019)

Significant increased CA199 levels in acute pancreatitis patients predicts the presence of pancreatic cancer
por: Teng, Dongling, et al.
Publicado: (2018)

Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?
por: Woei-A-Jin, F J Sherida H, et al.
Publicado: (2016)

Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer
por: Ali, Fahmy T., et al.
Publicado: (2022)

Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
por: Pujol, J. L., et al.
Publicado: (1993)

Comparison of diagnostic values between CA125 combined with CA199 and ultrasound combined with CT in ovarian cancer
por: Guo, Bingcheng, et al.
Publicado: (2019)

Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer
por: Zhang, Jun, et al.
Publicado: (2021)

CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
por: Coppola, Alessandro, et al.
Publicado: (2021)

Correlation of Serum CA242, CA724, and TPA Levels with Clinicopathological Features and Prognosis in Patients with Inflammatory Bowel Disease Complicated with Rectal Cancer
por: Liang, Hongliang, et al.
Publicado: (2022)

Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis
por: Guo, Junhong, et al.
Publicado: (2017)

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays
por: Song, Jin, et al.
Publicado: (2021)

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis
por: Qing, Xiaolin, et al.
Publicado: (2022)

A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer
por: Chen, Junliang, et al.
Publicado: (2022)

Diagnostic value of an enhanced MRI combined with serum CEA, CA19-9, CA125 and CA72-4 in the liver metastasis of colorectal cancer
por: Zhu, Hua-qiang, et al.
Publicado: (2022)

Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant
por: Liu, Wei, et al.
Publicado: (2018)

Diagnostic Significance of Serum IgG Galactosylation in CA19-9-Negative Pancreatic Carcinoma Patients
por: Zhong, Ailing, et al.
Publicado: (2019)

Retracted: A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_usehq7pde2nrafae8avd29ud2i